Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Notes Payables (2019 - 2025)

Quantum Biopharma's Notes Payables history spans 7 years, with the latest figure at $1.3 million for Q4 2025.

  • On a quarterly basis, Notes Payables rose 110.1% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 110.1% increase, with the full-year FY2025 number at $1.3 million, up 110.1% from a year prior.
  • Notes Payables hit $1.3 million in Q4 2025 for Quantum Biopharma, down from $2.0 million in the prior quarter.
  • Over the last five years, Notes Payables for QNTM hit a ceiling of $2.0 million in Q3 2025 and a floor of $300549.0 in Q2 2021.
  • Historically, Notes Payables has averaged $622636.4 across 5 years, with a median of $300549.0 in 2021.
  • Biggest five-year swings in Notes Payables: crashed 77.17% in 2021 and later soared 557.23% in 2025.
  • Tracing QNTM's Notes Payables over 5 years: stood at $300549.0 in 2021, then changed by 0.0% to $300549.0 in 2022, then changed by 0.0% to $300549.0 in 2023, then soared by 105.97% to $619029.0 in 2024, then soared by 110.1% to $1.3 million in 2025.
  • Business Quant data shows Notes Payables for QNTM at $1.3 million in Q4 2025, $2.0 million in Q3 2025, and $1.9 million in Q2 2025.